Drug Profile
Sarizotan - Newron Pharmaceuticals
Alternative Names: EMD-128130; Sarizotan hydrochlorideLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Merck KGaA
- Developer Merck KGaA; Newron Pharmaceuticals
- Class Antiparkinsonians; Antipsychotics
- Mechanism of Action 5-HT1A serotonin receptor agonists; Dopamine D2 receptor partial agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Drug-induced dyskinesia; Rett syndrome
Most Recent Events
- 04 May 2020 Discontinued - Phase-II/III for Rett syndrome (In adolescents, In children, In adults) in Australia (PO)
- 04 May 2020 Discontinued - Phase-II/III for Rett syndrome (In adolescents, In children, In adults) in India (PO)
- 04 May 2020 Discontinued - Phase-II/III for Rett syndrome (In adolescents, In children, In adults) in Italy (PO)